|
The new study, presented
at the American Federation of Medical Research, was conducted by John
Folts, PhD, professor of medicine and director of the Coronary Artery
Thrombosis Research and Prevention Laboratory at the University of Wisconsin
Medical School. Researchers used a patented compound developed by Idaho
Falls-based Melaleuca, Inc. containing flavonoids from grapeseed, grape
skin, Ginkgo biloba and bilberry extracts. Preliminary data on 20 dogs
and 12 humans indicate that the supplement is an effective inhibitor of
platelet aggregation, as well as an antioxidant. The formulation reduced
platelet activity by an average of 52%, roughly the same rate as aspirin,
according to Folts. The research suggests that the flavonoid supplement
may be a better platelet inhibitor than aspirin, not only because it maintains
its effectiveness in the presence of elevated adrenaline in the blood,
but because it also reduces the effects of another platelet stimulant,
adenosine di phosphate. And unlike aspirin, the supplement exhibits powerful
antioxidant properties that soak up "free radical" oxygen molecules
associated with heart disease. |
|